- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Dupilumab Prefilled Syringe
- Biological
- Lead sponsor
- Jonathan A. Bernstein, MD
- Other
- Eligibility
- 19 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hereditary Angioedema
- Interventions
- Ruconest
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Cincinnati, Ohio
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- benralizumab, placebo
- Biological
- Lead sponsor
- Jonathan A. Bernstein, MD
- Other
- Eligibility
- 19 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Asthma
- Interventions
- CREON2000A
- Device
- Lead sponsor
- General Innovations and Goods, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Homestead, Florida • Lexington, Kentucky • Cincinnati, Ohio + 4 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab 300 mg
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio